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SurgObjectives: Partial-support left ventricular assist devices (LVADs) represent a novel strategy for heart failure
treatment. The Synergy Pocket Micro-pump (HeartWare Inc, Framingham, Mass), the smallest surgically im-
planted long-term LVAD, provides partial flow up to 4.25 L/min and was primarily designed for ‘‘less sick’’ pa-
tients with severe heart failure. This device is implanted minimally invasively without sternotomy or
cardiopulmonary bypass. Early implantation in patients with Interagency Registry for Mechanically Assisted
Circulatory Support class 4 and higher was shown to be feasible and associated with significantly improved he-
modynamics and quality of life. The aim of this study was to present our experience with implementation of
long-term partial circulatory support as a bridge to transplantation in patients with more advanced heart failure
who were dependent preoperatively on inotropic support or intra-aortic balloon pump.
Methods: In this observational study, only inotropic or intra-aortic balloon pump–dependent patients with end-
stage heart failure were included (n ¼ 12). These patients underwent Synergy device implantation between
February 2012 and August 2013.
Results: The mean preoperative Interagency Registry for Mechanically Assisted Circulatory Support class was
2.17 0.84 (class 1, 25%; class 2, 33%; class 3, 42%). Themean agewas 46 15 years, and 33%were female.
Preoperatively, 4 patients (33%) had at least 1 previous sternotomy, 3 patients (25%) were supported with a
balloon pump, 1 patient (8%) had a previous full-support LVAD, and 4 patients (33%) had cerebrovascular
events in the past. After device implantation, there were no right ventricular failures, device-related infections,
hemorrhagic strokes, arterial or venous thromboembolisms, or worsenings of aortic and mitral regurgitation
observed over the follow-up. The mean follow up was 174  171 days (range, 5-764 days; cumulative, 3199
days). One patient (8%) died, 3 patients (25%) successfully underwent transplantation, 1 device (8%) was ex-
planted after myocardial recovery, and 5 patients (42%) are still on ongoing support. Two patients (17%) were
upgraded to a full-support LVAD after 65 days of mean support. A total of 11 of 12 patients (92%) were dis-
charged from the hospital and are presently alive. Left ventricular end-diastolic diameter was significantly
reduced 3 months after device implantation.
Conclusions: Partial LVAD support may be clinically efficacious in inotropic and intra-aortic balloon pump–
dependent patients. On the basis of our experience and evidence of previous research, such patients may benefit
fromminimally invasive access, no need for sternotomy and cardiopulmonary bypass, a short implantation time,
an easy exchange if necessary, and a lower risk of subsequent heart transplantation. Because the implantation is
performed without sternotomy, device upgrade is feasible with a comparatively low operative risk and good clin-
ical outcome. Our preliminary results show that partial-support devices may have the potential to replace full-
support LVADs in the near future. (J Thorac Cardiovasc Surg 2014;148:1115-22)e Department of Cardiothoracic Transplantation and Mechanical Circulatory
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Abbreviations and Acronyms
IABP ¼ intra-aortic balloon pump
INR ¼ international normalized ratio
INTERMACS ¼ Interagency Registry for
Mechanically Assisted Circulatory
Support
LVAD ¼ left ventricular assist device
RVF ¼ right ventricular failure
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XCardiac transplantation remains the gold standard therapy
for patients with end-stage heart failure. However, because
of significantly restricted donor organ availability in a num-
ber of countries resulting in increased waiting times and
mortality,1 left ventricular assist devices (LVADs) are
increasingly being applied as a life-sustaining bridge
to transplantation.2,3 Over the last 2 decades, major
technologic improvements in mechanical circulatory
support have been achieved, leading to the development
of significantly smaller and more reliable continuous-flow
systems.4 In addition to these full-support devices that can
provide up to 10 L/min of flow, partial-support devices
recently became available.
The Synergy Pocket Micro-pump (HeartWare Inc, Fra-
mingham, Mass) is the smallest surgically implanted
long-term LVAD, provides partial flow up to 4.25 L/min,
and was designed for patients with severe heart
failure without inotropic dependence (Interagency
Registry for Mechanically Assisted Circulatory Support
[INTERMACS] class 4-7).5 Early implantation of this
partial-support device in such patients was shown to be
feasible and associated with significantly improved
hemodynamics, end-organ perfusion, and quality of life.
In the majority of patients, the device prevented progression
to end-stage heart failure.5-7 One of the most important
benefits of this device is that it can be implanted with
minimally invasive access with no need for sternotomy,
resulting in fewer postoperative adverse events.
In view of the reports of the successful treatment of low-
risk patients with the Synergy Pocket Micro-pump, the
question arises as to whether patients eligible for a full-
support LVAD also would benefit from the Synergy device
as a bridge to transplantation. The aim of this study was
to present the outcomes of inotropic-dependent patients
undergoing long-term partial support as a bridge to
transplantation.
PATIENTS AND METHODS
Study Population
The study design was a retrospective review of the prospectively
collected data and did not require ethical approval. Data were collected
from the UK national ventricular assist device database. Twelve consecu-
tive patients dependent on an inotropic or intra-aortic balloon pump
(IABP) were included who underwent long-term support with the Synergy1116 The Journal of Thoracic and Cardiovascular SurLVAD between July 2007 and August 2013 in Harefield Hospital and Uni-
versity Hospital Goettingen. Implantation strategy was as a bridge to trans-
plantation for therapy-refractory end-stage heart failure. Prospectively
collected data included detailed information on patients’ demographics
and baseline clinical characteristics, laboratory, echocardiographic and he-
modynamic parameters, and intraoperative variables and postoperative
outcomes.
Definitions
Liver failure was defined as a 2-fold elevation of the upper limit of the
normal range of at least 2 liver function parameters. Any postoperative
renal dysfunction that required dialysis/hemofiltration was defined as renal
failure. Respiratory failure was defined as any impairment of respiratory
function requiring reintubation or mechanical ventilation after LVAD im-
plantation. Right ventricular failure (RVF) was defined as impairment of
right-sided function resulting in the need for a short-term or long-term right
ventricular assist device.
Surgical Techniques
All Synergy Pocket Micro-pump implantations were performed off-
pump as described previously.2,3,6,7 Preparation for left atrial cannulation
was performed by exposure of the confluence of the right pulmonary
veins through a 7- to 10-cm right-sided thoracotomy in the fourth inter-
costal space. In all cases, the pericardiumwas opened directly over the pul-
monary veins to provide direct access to the cannulation area. An additional
4-cm subclavicular incision was made for the formation of a small subcu-
taneous pocket. The pump was then placed in the subcutaneous tissue infe-
rior to the subclavian artery and frontal to the right pectoralis major muscle.
After heparin administration, a silicone inflow cannula with a titanium tip
and Dacron cuff was inserted into the left atrium using the Seldinger tech-
nique between the insertions of the right upper and lower pulmonary veins
and secured with two 4-0 polypropylene purse string sutures. The proximal
end of the cannula was tunneled through the second intercostal space to the
subcutaneous pocket. A polytetrafluoroethylene outflow graft was used to
perform an end-to-side anastomosis to the right subclavian artery. After
retrograde de-airing of the pump, the proximal end of the inflow graft
was connected to the device and the pump was started. Under echocardio-
graphic monitoring, the pump speed was then gradually increased from
20,000 rpm to a maximum of 28,000 rpm. While increasing the speed of
the device, pump current, cardiac output, pulmonary artery wedge pressure,
and arterial pressure were monitored with echocardiographic visualization
of the flow from the left atrium into the device. After setting up the final
speed and flow at approximately 3 L/min, the surgical wounds were closed
using the standard method.
Driveline Placement
In all cases, the percutaneous driveline was externalized after a short
subfascial course directly under the right subcostal margin.
Anticoagulation Protocol
Intravenous heparin was administered postoperatively after a minimumof
12 hours as a continuous infusion to progressively increase activated partial
thromboplastin time to 50 to 70 seconds when the cumulative chest tube
drainage decreased to less than 50 mL/h and the coagulation profile returned
to near normal levels. Platelet aggregation inhibitorswere used as a part of the
anticoagulation protocol; 75 mg of aspirin and 75 mg of clopidogrel daily
were immediately started after extubation. After chest drain removal and
tolerating oralmedication,warfarinwas administered tomaintain the interna-
tional normalized ratio (INR) between 2.5 and 3.5. The heparin infusion was
continued until the INR range was attained. In cases when INR decreased to
less than2.5 andpatientswere not on heparin infusion, low-molecular heparin
was used in a usual dose of 1.5 mg/kg body weight to ensure an appropriate
anticoagulation status during this time period.gery c September 2014
TABLE 1. Patient demographics and preoperative baseline
characteristics
Characteristics Value
Demographic data
Age (y) 46.1  14.6
Female 4 (33.3%)
Height (cm) 171.3  8.3
Weight (kg) 78.9  17.1
Primary diagnosis
DCM 8 (66.7%)
ICM 4 (33.3%)
Comorbidities
Hypertension 3 (25%)
COPD 3 (25%)
Diabetes mellitus 2 (16.7%)
PVD 0
History of cerebrovascular events 4 (33.3%)
History of cardiac arrest 1 (8.3%)
Other clinical data
Time since first cardiac diagnosis (mo) 115  79
Previous sternotomy 4 (33.3%)
Previous thoracotomy 1 (8.3%)
Previous acute MI 4 (33.3%)
Mechanical ventilation 1 (8.3%)
Hemodialysis 1 (8.3%)
Ascites 0
ICD 8 (66.7%)
Current smoker 2 (16.7%)
INTERMACS class
1 3 (25%)
2 4 (33.3%)
3 5 (41.7%)
COPD, Chronic obstructive pulmonary disease; DCM, dilated cardiomyo-
pathy; ICD, internal cardioverter defibrillator; ICM, ischemic cardiomyopathy;
INTERMACS, Interagency Registry for Mechanically Assisted Circulatory Support;
MI, myocardial infarction; PVD, peripheral vascular disease.
TABLE 2. Patient preoperative hemodynamic and echocardiographic
parameters
Characteristics Value
MCS
IABP support 3 (25.0%)
Previous full-flow LVAD support 1 (8.3%)
Hemodynamic status
Inotropic support 12 (100%)
Milrinone 8 (66.7%)
Dobutamine 3 (25.0%)
Adrenaline 2 (16.7%)
Noradrenaline 2 (16.7%)
Levosimendan 1 (8.3%)
Arrhythmia 3 (25.0%)
Heart rate (beats/min) 88.6  16.2
QRS-complex duration (ms) 143.6  10.4
CVP (mm Hg) 12.1  6.6
MPAP (mm Hg) 37.7  13.8
Wedge (mm Hg) 25.1  5.6
CI (L/m2) 1.9  0.8
SvO2 (%) 66.7  10.2
Lactate (mmol/L) 1.5  0.4
Echocardiographic parameters
LVEDD (mm) 71.8  9.2
LVESD (mm) 65.3  9.8
EF (%) 21.1  11.1
MR (grade)
No 0
Trivial 6 (50%)
Mild 4 (33.3%)
Moderate 0
Severe 2 (16.7%)
TR (grade)
No 1 (8.3%)
Trivial 5 (41.7%)
Mild 3 (25.0%)
Moderate 0
Severe 3 (25.0%)
AR (grade)
No 6 (50.0%)
Trivial 6 (50.0%)
Mild 0
Moderate 0
Severe 0
AR, Aortic valve regurgitation; CI, cardiac index; CVP, central venous pressure; EF,
ejection fraction; IABP, intra-aortic balloon pump; LVAD, left ventricular assist
device; LVEDD, left ventricular end-diastolic diameter; LVESD, left ventricular
end-systolic diameter; MPAP, mean pulmonary artery pressure; MR, mitral valve
regurgitation;MCS, mechanical circulatory support; SvO2, central venous saturation;
TR, tricuspid valve regurgitation.
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All data were analyzed using the Statistical Package for Social Sciences
version 21.0 (SPSS Inc, Chicago, Ill) and are presented as continuous or
categoric variables. Continuous data were evaluated for normality using
1-sample Kolmogorov–Smirnov test and confirmed by histograms. Contin-
uous variables were expressed as the mean standard deviation in cases of
normal distributed variables or median (interquartile range) in cases of non-
normally distributed variables. Categoric variables are presented as total
numbers of patients and percentages. Laboratory test changes over the peri-
operative course were analyzed with paired t test for normally distributed
variables. Kaplan–Meier survival estimation was applied for survival anal-
ysis of the entire patient cohort. Patients who underwent cardiac transplan-
tation, device exchange for device failure, or device explantation for
myocardial recovery were censored.T
XRESULTS
Patient demographics and preoperative baseline charac-
teristics are presented in Table 1. The mean age of the study
cohort was 46.1  14.6 years, and 33.3% of patients were
female. Dilated cardiomyopathy was the primary diagnosis
in the majority of patients (66.7%), followed by ischemicThe Journal of Thoracic and Carcardiomyopathy (33.3%). Patients with congenital heart
defects, peripartum dilated cardiomyopathy, and hypertro-
phic obstructive cardiomyopathy were not present in our
cohort. Inotropic support was started in all patients preoper-
atively to maintain acceptable end-organ function. Never-
theless, only 41.7% remained relatively stable, whereas
33.3% had progressive deterioration in hemodynamicsdiovascular Surgery c Volume 148, Number 3 1117
TABLE 3. Patient preoperative laboratory parameters
Characteristics Value
Laboratory parameters
BNP (pg/mL) 1597  1016
Sodium (mmol/L) 135.3  3.1
Potassium (mmol/L) 4.4  0.8
BUN (mg/dL) 9.6  2.6
Creatinine (mmol/L) 92.3  19.8
GFR 54.5  20.5
Albumin (g/L) 37  6.0
Total bilirubin (mmol/L) 27.9  28.9
INR 1.4  0.5
Platelets (3109/L) 210  57
ALT (U/L) 40.7  25.9
WCC (3109/L) 8.9  4.2
CRP (mg/L) 11.1  13.8
ALT, Alanine aminotransferase; BNP, brain natriuretic peptide; BUN, blood urea ni-
trogen; CRP, C-reactive protein; GFR, glomerular filtration rate; INR, international
normalized ratio; WCC, white blood cell.
TABLE 4. Preoperative medication
Drug
ACE inhibitor 4 (33.3%)
Angiotensin II receptor antagonist 4 (33.3%)
Beta-blocker 9 (75.0%)
Amiodarone 2 (16.7%)
Aldosterone antagonist 4 (33.3%)
Loop diuretic 11 (91.7%)
Oral anticoagulants 3 (25%)
Platelet inhibitor 3 (25.0%)
Digoxin 2 (16.7%)
Other antiarrhythmic drug 1 (8.3%)
ACE, Angiotensin-converting enzyme.
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Xand end-organ function. Some 25% of patients were in
cardiogenic shock at the time of LVAD implantation despite
increasing inotropic and additional IABP support (Tables 1
and 2). The high-risk status of the present patient cohort is
underlined by deranged preoperative hemodynamics and
echocardiographic parameters (Table 2). The mean pulmo-
nary capillary wedge pressure was 25.1 5.6 mmHgwith a
mean cardiac index of less than 2 with left ventricular end-
diastolic dimensions showing severe left ventricular dilata-
tion with a mean ejection fraction of 21.1% 11.1%. Two
patients had severe mitral regurgitation at the time of
partial-support LVAD implantation. Also, 33.3% of pa-
tients had at least 1 previous sternotomy (range, 1-5), and
1 patient had a previous thoracotomy. Of these patients, 1
had been supported with a full-flow long-term LVAD that
was subsequently explanted for myocardial recovery.
Preoperative laboratory parameters are shown in Table 3.
The severity of heart failure also can be assessed by the
deranged laboratory values indicating impaired end-organ
function. Patients had increased mean brain natriuretic pep-
tide, blood urea nitrogen, total bilirubin levels, and slightly
deranged alanine aminotransferase. Furthermore, despite
the fact that only 1 patient required hemodialysis preopera-
tively, the mean glomerular filtration rate was moderately
impaired and corresponded to stage 3 chronic kidney dis-
ease. At the same time, all patients who were not on hemo-
dialysis required preoperative treatment with diuretics
(Table 4). The details of preoperative heart failure drugs,
platelet inhibitors, and anticoagulants are shown in Table 4.
Postoperative outcomes, including major adverse events
after LVAD implantation, are shown in Table 5. In brief, 2
patients required postoperative hemodialysis for renal
failure, 1 patient had respiratory failure requiring
reintubation, and 2 patients had to be reopened for late chest
hematoma after a mean time of 14.5  4.9 days. Also,1118 The Journal of Thoracic and Cardiovascular Surnondevice-related infections developed in 2 patients over
the follow-up. One of them had confirmed bacterial infec-
tion from bronchoalveolar lavage on postoperative day 6,
and 1 developed a urinary tract infection that was diagnosed
on the postoperative day 12. Both infections were appropri-
ately treated with antibiotics and did not affect long-term
outcome. Neurologic dysfunction due to an embolic
cerebrovascular event developed in 1 patient, which lasted
for more than 24 hours. This patient died on postoperative
day 90, and this death was attributed to general clinical
deterioration with a background of multiorgan Fabri’s
disease, although the device continued to function satisfac-
torily. Four patients (33.3%) experienced pump thrombosis
and underwent device exchange.
Mild RVF requiring prolonged inotropic support or mod-
erate to severe RVF requiring a right-sided mechanical sup-
port did not develop in the patients from the present cohort.
Also, there were no significant early postoperative surgical
bleeding episodes requiring reopening and no device-
related infections.
Follow-up and Survival
The mean support duration was 266  229 days. The
longest support duration was 764 days, and this patient is still
on support and doing well. The overall cumulative survival
after partial-support LVAD implantation was 100% at 30
days and 88.9% at 6 months, 1 year, and 2 years (Figure 1).
Over the follow-up period, 3 patients (25%) successfully un-
derwent transplantation, 1 patient underwent LVAD explan-
tation for myocardial recovery, 2 patients (16.7%) were
upgraded to a full-support LVAD (HVAD, HeartWare Inc),
and 5 patients (44.3%) are still being supported.
DISCUSSION
LVADs are being used increasingly for patients with
advanced heart failure as a bridge to transplantation in
response to waiting list mortality because of the donor heart
scarcity.2,3 Currently, full-support LVADs still remain the
most widely used assist systems.8,9 Recent developments
in the field of circulatory assist have resulted in thegery c September 2014
TABLE 5. Postoperative outcomes
Characteristics Value
Postoperative outcomes
Inotropic support duration (d) 2 (1-7)
Ventilation duration (d) 1 (1-1)
Mild RVF* 0
Moderate to severe RVFy 0
Hemodialysis 2 (16.7%)
Reintubation 1 (8.3%)
ICU LOS (d) 4 (1-12)
Total hospital LOS (d) 32 (19-90)
Transfusions (units within 7 d) 8 (2-18)
RBC 0.5 (0-3.5)
Platelets 0 (0-1)
FFP 0 (0-2.75)
Need for revision because of postoperative bleeding 0
Need for revision because of late hematoma 2 (16.7%)
Infections
Nondevice-related infections 2 (16.7%)
Device-related infections 0
Long-term outcomes
Support duration (d) 266.6  229.9
Upgrade to a full-support LVAD 2 (16.7%)
Ongoing support 5 (41.7%)
Died on support 1 (8.3%)
Transplanted 3 (25.0%)
Explanted for recovery 1 (8.3%)
Need for device exchange for device failure 4 (33.3%)
Neurologic complication
Ischemic CVA 1 (8.3%)
Hemorrhagic CVA 0
Seizure 0
TIA 0
Other adverse events
Hemolysis 3 (25.0%)
Gastrointestinal bleeding 1 (8.3%)
MI 0
Wound dehiscence 1 (8.3%)
Venous thromboembolism 0
Cardiac arrhythmias 1 (8.3%)
CVA, Cerebrovascular accident; FFP, fresh-frozen plasma; ICU, intensive care unit;
LOS, length of stay; MI, myocardial infarction; RBC, red blood cells; RVF, right
ventricular failure; TIA, transient ischemic attack; LVAD, left ventricular assist
device. *Requiring inotropic support for>14 days. yRequiring right-sided mechani-
cal support.
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Xsuccessful implementation of miniaturized partial-flow de-
vices intended for patients with severely symptomatic heart
failure but preserved end-organ function and no inotropic de-
pendency.5-7 However, the proportion of high-risk patients
requiring inotropic support or IABPbefore anLVADimplan-
tation has significantly increased in recent years.
This study is a 2-center experience of partial LVAD sup-
port as a bridge to transplantation in patients who were
dependent on inotropic support with or without an IABP.
In the present study, we showed that inotropic-dependent
patients may benefit from partial-support devices because
partial flow seems to be sufficient even under conditionsThe Journal of Thoracic and Carof low cardiac output. This finding may be attributable to
the rapid and less-invasive surgery required for Synergy
pump implantation, which may reduce morbidity and mor-
tality normally associated with full-support LVADs (which
in most cases is performed through median sternotomy and
with cardiopulmonary bypass). This promotes a quick re-
covery and return to normal activities, and early reinstitu-
tion on the transplant waiting list. If the Synergy device
needs to be replaced, this is a relatively straightforward
procedure.
The Synergy device achieved CE mark approval in Eu-
rope in September 2012. This pump was approved only
for patients with heart failure graded as INTERMACS class
4 and above.10 The device was not originally intended for
the treatment of patients with heart failure who are depen-
dent on inotropic support or IABP. Therefore, we describe
‘‘off-label’’ use of partial support in patients with more
advanced heart failure.
Over the last 2 decades, the number of full-support ven-
tricular assist devices implanted and the duration of support
and survival have increased significantly.11 However, the
long-term survival remains suboptimal, because LVAD im-
plantation is still associated with an unacceptably high
number of postoperative adverse events.4 This study dem-
onstrates that even in high-risk patients, the device is asso-
ciated with a lower rate of early complications, such as
surgical bleeding, infections, thromboembolism, and RVF.
In particular, freedom from the RVF in all patients from
our cohort is a significant advantage of the Synergy device
compared with full-support systems. Also, recognized
major late complications, such as device-related infections,
cerebrovascular events, and development of aortic regurgi-
tation, seem to occur less frequently with the Synergy
device than in full-support devices. The only major long-
term complication of partial-support devices that has been
described and remained a significant limitation of the
current study is device failure primarily due to pump throm-
bosis. However, an even higher incidence of device throm-
bosis was reported after initial clinical implementation of an
intrapericardial continuous-flow, full-support device.12 The
results of a subsequent retrospective analysis of the ex-
planted pump impellers and the pump manufacturing tech-
niques led to a change in the impeller geometry and tighter
specifications for the thrust-bearing dimensions. These
technologic changes significantly improved outcomes
with significantly less device failures due to thrombosis.12
For that reason, further refinement of the Synergy impeller
design is likely to result in a further reduction in the rate of
pump thrombosis. Also, the development of further partial-
support devices should be conducted focusing on preven-
tion of this major complication. Nevertheless, as described
in previous research and confirmed by our experience, the
Synergy pump exchange can be performed more easily
and quickly than a full-support LVAD, similar to adiovascular Surgery c Volume 148, Number 3 1119
FIGURE 1. Kaplan–Meier survival curve for the entire cohort of patients who underwent partial-support LVAD implantation. Patients are censored for
cardiac transplantation, device explantation for myocardial recovery, device exchange, and at the cutoff of the study. Twenty-day, 6-month, 1-year, and
2-year cumulative survivals with respective numbers of patients at risk are shown.
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because neither sternotomy nor inflow/outflow cannulae ex-
change is needed.13
In general, our outcomes with partial support are similar
to those described in previous studies of patients for whom
the Synergy device was originally intended, that is, less-
advanced heart failure. However, in our patient cohort, there
may be a relatively high risk of the requirement for an up-
grade to a full-support device because of late deterioration
in hemodynamics and clinical condition. This might be
explained by the fact that partial support in ‘‘less sick’’ pa-
tients was designed to prevent possible deterioration of rela-
tively stable patients and avoid the need for a full-support
LVAD.5-7 However, our cohort consisted of patients who
were already on inotropic support, with progressive
decline in end-organ function or even cardiogenic shock.
Nevertheless, as shown in our study, the partial support
was sufficient for the majority of patients, and an upgrade
to a full-support LVAD was necessary in only 2 patients
(16.7%). In the first case, the patient who was dependent
on IABP and inotropic support preoperatively remained
supported with an IABP during the first 5 postoperative
days. After unsuccessful attempts to wean off the balloon1120 The Journal of Thoracic and Cardiovascular Surpump, the decision was made to implant a full-support
LVAD through median sternotomy. Because the patient
had no previous sternotomy, the upgrade LVAD implanta-
tion was similar to a first LVAD implantation and was not
considered re-do surgery. However, if the Synergy device
is replaced with a full-flow LVAD, care must be taken to
ensure the left atrial cannulation site is closed meticulously,
otherwise air may be entrained when full LVAD support is
initiated. The patient had a rapid subsequent recovery and
was placed on our transplant waiting list. Of note, this pa-
tient’s low weight and relatively well-preserved preopera-
tive cardiac output were considered as reasons for
proceeding with partial support, but despite this, he subse-
quently required full support.
In the second case, the partial support was successful for
approximately 4 months, and the patient was discharged.
Nevertheless, an upgrade to full support had to be per-
formed after sudden deterioration in cardiac function with
rapidly increasing heart failure symptoms. After full-
support LVAD implantation, the patient was discharged
and subsequently placed on our transplant waiting list and
underwent transplantation. Despite the fact that this patient
was free of inotropic support after partial support had beengery c September 2014
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months of uneventful follow-up, we do not consider this
case a clinical success because the patient was not bridged
to transplantation with only partial support. However, it
might have been considered successful if we had received
a suitable organ offer during this uneventful timeframe on
Synergy pump support. Both examples show that an up-
grade of partial-support LVAD to a full-support LVAD
might be necessary in individual patients. Because of a
low number of cases with partial support in inotropic/
IABP-dependent patients and no obvious reasons for deteri-
oration, the predictors of early or late upgrade to a full-
support LVAD warrant further investigations.
Because the Synergy pump is located outside the pericar-
dium, the sternotomy and excision of the native heart during
the heart transplantation are not associated with extensive
and time-consuming dissection and may significantly
decrease the total ischemic time, which is advantageous.
The pump can be stopped and excised before or after im-
planting the donor heart. Furthermore, in case of primary
graft failure, it is conceivable that the Synergy pump could
be restarted to temporarily support the donor heart before
weaning and explantation at a later date.
In the present study, the survival was 100% at 30 days
and 88.9% at 1 and 2 years, which is not inferior, if not
better, than the survival in patients in full-flow LVAD
trials.5-7 These results demonstrate that the novel device
configuration can be clinically efficacious even in patients
with more advanced heart failure, and that the partial-
support idea has a potential utility in a wide range of pa-
tients with severe heart failure. Despite recently reported
technical issues regarding the Synergy Pocket Micro-
pump14 and the need for improvement in the pump throm-
bosis rate, the general idea of partial support seems to be
a valuable option for patients with heart failure. Further-
more, our preliminary evidence suggests that partial flow
might be sufficient even in patients with low cardiac output.
Additional benefits due to the less-invasive access, fewer
complications, and a lower cardiac transplantation risk
might precipitate an increasing use of partial-support de-
vices. In summary, the current answer to the question:
‘‘Do we still need full-support LVADs?’’ is ‘‘Yes, we do.’’
However, potential technologic improvements and develop-
ment of new reliable devices may significantly increase the
proportion of patients with heart failure who can be bridged
to transplantation using partial-flow LVADs. However,
because there is a risk of deterioration on partial support,
the need to refine patient selection criteria particularly in
cases with more advanced heart failure remains an impor-
tant target for further investigations.
Study Limitations
A 2-center experience with a small cohort of patients has
been presented. However, the total number of SynergyThe Journal of Thoracic and Cardevices implanted in patients worldwide is comparatively
small. Furthermore, this device is currently undergoing an
upgrade to resolve issues that arose after initial commercial
release. Surgical system sales are expected to resume in a
controlled fashion after regulatory approval to relaunch
the system in Europe.CONCLUSIONS
Partial LVAD support may be clinically efficacious in
inotropic and IABP-dependent patients. On the basis of
our experience and evidence of previous research, such pa-
tients may benefit from minimally invasive access, no need
for sternotomy and cardiopulmonary bypass, a short im-
plantation time, an easy exchange if necessary, and a lower
risk of subsequent heart transplantation. Because the im-
plantation is performed without sternotomy, device upgrade
is feasible with a comparatively low operative risk and good
clinical outcome. Our preliminary results show that partial-
support devices may have the potential to replace full-sup-
port LVADs in the near future.References
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XDiscussion
Dr Kavous Hakim-Meibodi (Bad Oeynhausen, Germany).
Thank you, Dr Sabashnikov, for presenting your work pushing
the limits on the treatment of very ill patients with failing left ven-
tricular function. Since the first implantation of the device in 2008,
it has been on and off the market several times for technical prob-
lems. Finally, the CE mark was achieved in 2012.
In your current study, you have achieved some remarkable re-
sults using this device for very ill patients, INTERMACS class I
to III. I congratulate you on these results. On the other hand,
perhaps some of the reported results need some second thought.
You reported the variety of patients in INTERMACS class I to
III. What were the criteria to use this device for this kind of patient
instead of the full LVAD?
Dr Sabashnikov.At that time, we didn’t have any data on using
this device in patients with INTERMACS classes higher than IV
because the device was actually approved for less sick patients
without inotropic dependency.
However, we thought some patients would benefit from this de-
vice, and we implanted it preferably in patients with low body
mass index and with deterioration that had started recently with
still available cardiac output. Because our idea was that despite
low flow of a maximum of 4.25 liters, this support was being added
to the remaining cardiac output of patients. Cardiac output was
enough for most of them. That was the main idea why we started
using the device in inotropic-dependent patients.
Our results showed that only 16% of patients had to be upgraded.
As Imentioned, the risk of upgrade is lower because it’s thefirst ster-
notomy, and it should not be considered a redo procedure.
Dr Hakim-Meibodi. Four of 12 patients had pump thrombosis.
In my opinion, this is a high rate. I guess it’s device related. How
did you proceed? Did you just exchange the pump or also the
inflow part, which is intrathoracal?
Dr Sabashnikov. Device thrombosis is the most important part
of this story because a high number of complications occurred.
However, the device is new, and I have to mention that other de-
vices had similar problems in the beginning, and after several
manufacturer changes, the quality of the devices improved.
So now we are in the phase when this device is being refined.
Some manufacturer changes are being performed, and we hope
that next year we will have a completely new version of this: a par-
tial-support device with significantly lower risk of thrombosis. In
all cases, we treat thrombosis by exchanging the device because
it’s a short and easy procedure. In all cases, we leave the inflow
cannula in situ. However, we left the clamp open for a couple of
seconds to be sure that the cannula is free of thrombi.
Dr Hakim-Meibodi. Don’t you think this small inflow cannula
far from the pump is one of the reasons for the thrombosis, the sys-
tematic problem for this device?
Dr Sabashnikov. No. According to our investigations, most
thrombotic structures occurred in the pump itself, so we were
not really worried about the cannula.
Dr Hakim-Meibodi. Don’t you think this high rate of throm-
bosis is particularly dangerous in this pump-dependent group of
patients? So this is something that is well tolerated if the patient
has enough rest output, but if he’s depending on the pump, it could
be a severe problem.1122 The Journal of Thoracic and Cardiovascular SurDr Sabashnikov. Sure. We were lucky that all pump thrombo-
ses occurred when patients were still in the hospital, and patients
theoretically might have been put on inotropic support, but we
managed to do it without. Nevertheless, that’s a good point that
inotropic-dependent patients might deteriorate because of low car-
diac output, at home if they develop pump thrombosis and still
have not recovered at least a little bit. However, it can happen
with any device.
DrHakim-Meibodi.You reported 1 patient who already had an
LVAD. What were the criteria to implant this pump in this patient
and what did you do to the assist device? Did you explant it?
Dr Sabashnikov. It was a young patient who had undergone im-
plantation with a full-flow assist device via median sternotomy a
long time ago, and he underwent explantation of the assist device
because of myocardial recovery later and was free of heart failure
symptoms for a long period of time. Once he developed heart
failure symptoms again and was deteriorating, we decided to go
for a less-invasive procedure because of the previous full
sternotomy.
Dr Nader Moazami (Cleveland, Ohio). The concept of partial
support is interesting, specifically in the very sick patients who
have received this device. I think we always use the yardstick of
survival as a measure of success.
What I didn’t see in your presentation is how do the hemody-
namics of these patients improve? What was the functional status
of these patients? Were any discharged or were they in the hospital
all the time?
The reason I say that is because, as you know, this technology is
now off the shelf because of multiple problems. Thrombosis is just
one of the problems. There are many other problems, and there are
other pumps that can now be implanted through minithoracoto-
mies that can provide full support. So we should be careful, specif-
ically because of the bad experience with left atrial cannulation in
general. What was the functional status of these patients?
Dr Sabashnikov. One patient died. All other patients under-
went transplantation or are on ongoing support, and all of them
were discharged.
Regarding your good points, we are now in the beginning area
of this partial support and already have seen results. Thrombosis
and other complications that occurred during LVAD support in
the beginning are normal signs, and that’s why the device is tempo-
rarily suspended. But our general idea is not related to this partic-
ular device but to the partial support in general. So people can use
this information after development of new partial-flow devices,
and particularly after the Synergy device has been upgraded to a
better model and is available on the market again.
DrOztekin Oto (Izmir, Turkey). Youmentioned that you had no
RVF at all, although you are partially supporting and these are very
ill patients. What is the secret then, and what are your RVF
criteria?
Dr Sabashnikov.We are not sure, but it might be related to the
low transfusion rate because it’s a less invasive procedure without
sternotomy. Also, it’s a short implantation with lower trauma. But
it’s still unclear, because it’s a very new area.
Dr Jose Pomar (Barcelona, Spain). Just to tell you, the next
time, please remember that not everybody knows what the Synergy
pump is, and it would be nice to have a picture at the beginning.gery c September 2014
